# Rarity Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rarity-bioscience

- Industry: Biotechnology
- Headquarters: Uppsala, Sweden
- Website: www.raritybioscience.com/
- Total disclosed funding: $3.1M
- Latest round: Seed (Feb 6, 2023)
- Investors on record: 2

## About

Based in Sweden, and founded in 2021 by Lei Chen, Per Matsson, Ulf Landegren, and Mikael Smedeby, Rarity Bioscience operates as biotechnology research company that develops better ways to detect very small amounts of DNA sequence variants. In June 2024, Rarity Bioscience raised EUR 6.5 million in venture funding led by returning investor Navigare Ventures, with participation from other returning investors Novalis Biotech and Uppsala University. Other unspecified investors also participated in the round.

Rarity Bioscience is a molecular diagnostics company that develops the superRCA technology for single variant mutation detection. The company's mission is to democratize mutation detection and improve clinical decisions and patient outcome by offering fast, sensitive, and reliable mutation detection technology. The company offers a various of applications, such as measurable residual disease (MRD) monitoring, which can be used to detect low levels of ctDNA in liquid biopsies, allowing for earlier detection of mutations, and analyzing both genomic and cell-free DNA in liquid biopsies, reducing the need for harmful tissue biopsies, and clinical trials, which are used to assess biomarkers in both pharma development and clinical testing.

## Funding rounds

- Seed, Feb 6, 2023, $0.5M — Novalis Biotech
- Seed, Nov 29, 2022, $2.6M — Navigare Ventures

## Investors

- Navigare Ventures (https://capitalatlas.ai/funds/navigare-ventures) — Seed
- Novalis Biotech (https://capitalatlas.ai/funds/novalis-biotech) — Seed